KYTHERA Biopharmaceuticals will be Presenting Phase 2 Data on Fat Reduction Drug at American Society for Dermatologic Surgery Meeting

 

On Friday October 2 at 11:00 AM, Kythera Biopharmaceuticals will be presenting Phase 2 Data on the ATX-101. ATX-101 is a novel, injectable drug for the reduction of localized fat.

woman showing double chin On Friday October 2 at 11:00 AM, Kythera Biopharmaceuticals will be presenting Phase 2 Data on the ATX-101 at the Scientific Session (CS263) - "You Asked for It".

ATX-101 is a novel, injectable drug for the reduction of localized fat. ATX-101 is intended to address the absence of an approved drug to reduce excess localized fat in the face. The drug is currently being tested for its effectiveness in reducing submental, or under the chin, fat.

While the market of minimally invasive non-surgical facial rejuvenation products has grown rapidly, there is currently no drug on the market that reduces facial fat deposits to restore and reshape the jaw line. Kythera is developing ATX-101 to meet the growing demand for such a product.

ATX-101 is a first in class-drug based on an endogenous compound. Unique features of the drug include selectivity for adipocytes and rapid clearance. Kythera is also developing several related drugs, including ATX-104 for facial contouring, and ATX-202 for pigmentation modulation. Kythera, the biotechnology company presenting the study, is a privately held biopharmaceutical company that uses the tools of biotechnology to develop prescription aesthetic therapies.

Kythera has completed two randomized, double blind placebo-controlled studies on ATX-101, as well as Phase 2 studies, and two Phase 1 pharmacokinetic and histology studies. Data slides highlighting the results from the new Phase 2 study will be available online on October 2 following the presentation.